Evaluation Protocol for STDs and PID
The evaluation protocol for STDs and PID requires a low threshold for diagnosis, with testing for N. gonorrhoeae and C. trachomatis in all suspected cases, followed by empiric treatment based on minimum clinical criteria to prevent long-term reproductive complications. 1
Diagnostic Criteria for PID
Minimum Clinical Criteria (Sufficient to Initiate Treatment)
Additional Criteria to Increase Diagnostic Specificity
- Oral temperature >38.3°C (>101°F) 1
- Abnormal cervical or vaginal discharge 1
- Elevated erythrocyte sedimentation rate and/or C-reactive protein 1
- Laboratory evidence of cervical infection with N. gonorrhoeae or C. trachomatis 1
Definitive Diagnostic Criteria (For Selected Cases)
- Histopathologic evidence of endometritis on endometrial biopsy 1
- Transvaginal sonography showing thickened fluid-filled tubes or tubo-ovarian complex 1
- Laparoscopic abnormalities consistent with PID 1
Required Laboratory Testing
For All Suspected PID Cases
For Suspected Vaginal Infections
- Vaginal pH testing (BV and trichomoniasis: pH >4.5; candidiasis: pH ≤4.5) 2
- Wet mount microscopy with saline and 10% KOH to identify trichomonads, yeast, or pseudohyphae 2
For Suspected Epididymitis
- Gram-stained smear of urethral exudate for diagnosis of urethritis 1
- Culture or nucleic acid amplification test for N. gonorrhoeae and C. trachomatis 1
- Examination of first-void urine for leukocytes 1
- Syphilis serology and HIV counseling/testing 1
Treatment Approach
Hospitalization Criteria for PID
- Uncertain diagnosis 1
- Surgical emergencies cannot be excluded 1
- Pelvic abscess is suspected 1
- Pregnancy 1
- Adolescent patient (compliance concerns) 1
- Severe illness precludes outpatient management 1
- Patient unable to tolerate outpatient regimen 1
- Failed outpatient therapy 1
- Clinical follow-up within 72 hours cannot be arranged 1
Follow-Up Requirements
- Patients should demonstrate substantial clinical improvement within 3 days after initiating therapy 1
- If no improvement occurs within 48-72 hours, reconsider alternative diagnoses or treatment 1
- Some experts recommend rescreening for C. trachomatis and N. gonorrhoeae 4-6 weeks after therapy 1
Management of Sex Partners
- Treatment of sex partners is imperative for patients with PID or STDs 1
- Sex partners should be examined and treated if they had sexual contact with the patient during the 60 days preceding symptom onset 1
- Empiric treatment for both C. trachomatis and N. gonorrhoeae is recommended for partners, regardless of PID etiology 1
- Special arrangements should be made to provide care for male partners in settings where only women are treated 1
Patient Education
- Explain the nature of the disease and encourage compliance with therapy 1
- Emphasize the need to take all medication regardless of symptom resolution 1
- Review contraindications and potential side effects 1
- Identify and address potential compliance problems 1
- Explain the purpose of follow-up evaluation 1
- Emphasize the need to avoid sex until treatment is completed 1
- Stress the importance of partner evaluation and treatment 1
Special Considerations
Pregnancy
- Pregnant women with suspected PID should be hospitalized and treated with parenteral antibiotics due to high risk for maternal morbidity, fetal wastage, and preterm delivery 1
HIV Infection
- Immunosuppressed HIV-infected women with PID should be managed aggressively using parenteral antimicrobial regimens 1
Common Pitfalls to Avoid
- Failure to recognize mild or atypical presentations of PID, leading to delayed treatment and increased risk of complications 1, 3
- Inadequate adherence to CDC treatment recommendations in clinical practice 4
- Treating empirically without proper diagnosis for vaginal infections 2
- Failing to treat sexual partners, particularly in cases of trichomoniasis 2
- Not maintaining a low threshold for diagnosis, as PID can cause significant reproductive damage even with mild symptoms 1
- Neglecting to screen asymptomatic patients for STIs according to guidelines, which may increase risk of both acute and subclinical PID 3